Tags

Type your tag names separated by a space and hit enter

Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 2012 May; 56(5):2493-503.AA

Abstract

The in vitro activities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by binding with high affinity for protein synthesis elongation factor Tu, fidaxomicin, and 10 other antimicrobial agents were determined against 50 strains of Clostridium difficile and 630 other anaerobic and aerobic organisms of intestinal origin. LFF571 possesses potent activity against C. difficile and most other Gram-positive anaerobes (MIC(90), ≤ 0.25 μg/ml), with the exception of bifidobacteria and lactobacilli. The MIC(90)s for aerobes, including enterococci, Staphylococcus aureus (as well as methicillin-resistant S. aureus [MRSA] isolates), Streptococcus pyogenes, and other streptococci were 0.06, 0.125, 2, and 8 μg/ml, respectively. Comparatively, fidaxomicin showed variable activity against Gram-positive organisms: MIC(90)s against C. difficile, Clostridium perfringens, and Bifidobacterium spp. were 0.5, ≤ 0.015, and 0.125 μg/ml, respectively, but >32 μg/ml against Clostridium ramosum and Clostridium innocuum. MIC(90) for S. pyogenes and other streptococci was 16 and >32 μg/ml, respectively. LFF571 and fidaxomicin were generally less active against Gram-negative anaerobes.

Authors+Show Affiliations

RM Alden Research Lab, Culver City, California, USA. d.m.citron@att.netNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22290948

Citation

Citron, Diane M., et al. "Comparative in Vitro Activities of LFF571 Against Clostridium Difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria." Antimicrobial Agents and Chemotherapy, vol. 56, no. 5, 2012, pp. 2493-503.
Citron DM, Tyrrell KL, Merriam CV, et al. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2012;56(5):2493-503.
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. (2012). Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrobial Agents and Chemotherapy, 56(5), 2493-503. https://doi.org/10.1128/AAC.06305-11
Citron DM, et al. Comparative in Vitro Activities of LFF571 Against Clostridium Difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria. Antimicrob Agents Chemother. 2012;56(5):2493-503. PubMed PMID: 22290948.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. AU - Citron,Diane M, AU - Tyrrell,Kerin L, AU - Merriam,C Vreni, AU - Goldstein,Ellie J C, Y1 - 2012/01/30/ PY - 2012/2/1/entrez PY - 2012/2/1/pubmed PY - 2012/8/18/medline SP - 2493 EP - 503 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 56 IS - 5 N2 - The in vitro activities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by binding with high affinity for protein synthesis elongation factor Tu, fidaxomicin, and 10 other antimicrobial agents were determined against 50 strains of Clostridium difficile and 630 other anaerobic and aerobic organisms of intestinal origin. LFF571 possesses potent activity against C. difficile and most other Gram-positive anaerobes (MIC(90), ≤ 0.25 μg/ml), with the exception of bifidobacteria and lactobacilli. The MIC(90)s for aerobes, including enterococci, Staphylococcus aureus (as well as methicillin-resistant S. aureus [MRSA] isolates), Streptococcus pyogenes, and other streptococci were 0.06, 0.125, 2, and 8 μg/ml, respectively. Comparatively, fidaxomicin showed variable activity against Gram-positive organisms: MIC(90)s against C. difficile, Clostridium perfringens, and Bifidobacterium spp. were 0.5, ≤ 0.015, and 0.125 μg/ml, respectively, but >32 μg/ml against Clostridium ramosum and Clostridium innocuum. MIC(90) for S. pyogenes and other streptococci was 16 and >32 μg/ml, respectively. LFF571 and fidaxomicin were generally less active against Gram-negative anaerobes. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/22290948/Comparative_in_vitro_activities_of_LFF571_against_Clostridium_difficile_and_630_other_intestinal_strains_of_aerobic_and_anaerobic_bacteria_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=22290948 DB - PRIME DP - Unbound Medicine ER -